The purpose of the study is to evaluate brain serotonin transporter (SERT) receptor occupancy (RO) following single oral doses of LG-0317 tablets in healthy male participants; and to explore the pharmacokinetic/pharmacodynamic (PK/PD) relationship between LG-0317 plasma concentrations and SERT occupancy..
Participant must weigh at least 50 kg to participate in the study, and must have a body mass index (BMI) within the range of 19-28 kg/m2 inclusive.
The participant has normal results or abnormalities without clinical significance as judged by the investigator for vital signs, physical examination, laboratory tests (complete blood count, blood biochemistry, coagulation function, urinalysis), 12-lead electrocardiogram (ECG.
Fully understand the trial content, procedures, and possible adverse reactions; voluntarily participate and sign the informed consent form (ICF).
Able to communicate well with the study personnel, and understand and comply with the relevant requirements of the trial.
1) Allergic constitution, history of allergic diseases, or known allergy to the investigational product, its excipients, or related products.
Parallel
Cohort 1: LG-0317 20 mg
DrugSubjects will receive single dose of LG-0317 tablets.
Cohort 1: LG-0317 40 mg
DrugSubjects will receive single dose of LG-0317 tablets.
Cohort 1: LG-0317 80 mg
DrugSubjects will receive single dose of LG-0317 tablets.
Receptor Occupancy: SERT occupancy in brain ROIs post single-dose of LG-0317 as measured by PET/CT.
Pharmacokinetics: maximum plasma concentration (Cmax)
Pharmacokinetics: time to reach Cmax(Tmax)
Pharmacokinetics: area under the plasma concentration-time curve from time zero to the last quantifiable concentration (AUC0-t)
Number of participants experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs)
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
